These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30877709)

  • 1. Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice.
    Hong AR; Koo BK; Kim SW; Yi KH; Moon MK
    Diabetes Metab J; 2019 Oct; 43(5):590-606. PubMed ID: 30877709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Dapagliflozin in Combination with Lobeglitazone and Metformin in Korean Patients with Type 2 Diabetes in Real-World Clinical Practice.
    Seo DH; Suh YJ; Cho Y; Ahn SH; Seo S; Hong S; Lee YH; Choi YJ; Lee E; Kim SH
    Yonsei Med J; 2022 Sep; 63(9):825-833. PubMed ID: 36031782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Efficacy and Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy in Patients With Type 2 Diabetes.
    Hussain M; Elahi A; Iqbal J; Bilal Ghafoor M; Rehman H; Akhtar S
    Cureus; 2021 Apr; 13(4):e14268. PubMed ID: 33954073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial.
    Bode B; Stenlöf K; Sullivan D; Fung A; Usiskin K
    Hosp Pract (1995); 2013 Apr; 41(2):72-84. PubMed ID: 23680739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
    Chen Z; Li G
    Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors as add-on to metformin and sulfonylurea treatment for the management of type 2 diabetes: a meta-analysis.
    Li J; Shao YH; Wang XG; Gong Y; Li C; Lu Y
    Endocr J; 2018 Mar; 65(3):335-344. PubMed ID: 29375082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Empagliflozin in Type 2 Diabetes Mellitus Saudi Patients as Add-On to Antidiabetic Therapy: A Prospective, Open-Label, Observational Study.
    Althobaiti FM; Alsanosi SM; Falemban AH; Alzahrani AR; Fataha SA; Salih SO; Alrumaih AM; Alotaibi KN; Althobaiti HM; Al-Ghamdi SS; Ayoub N
    J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efficacy and Safety of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors in Real-World Clinical Practice: Potential Cautionary Use in Elderly Patients with Type 2 Diabetes (T2D).
    Lee DH; Oh JH; Jeon HJ; Oh TK
    Diabetes Ther; 2024 Jul; 15(7):1615-1626. PubMed ID: 38771472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
    Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of sodium-glucose co-transporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus.
    Jiang A; Feng Z; Yuan L; Zhang Y; Li Q; She Y
    Diabetol Metab Syndr; 2021 Mar; 13(1):34. PubMed ID: 33766125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and effectiveness of dapagliflozin in patients with type 2 diabetes mellitus: a multicenter retrospective study in Taiwan.
    Chen JF; Peng YS; Chen CS; Tseng CH; Chen PC; Lee TI; Lu YC; Yang YS; Lin CL; Hung YJ; Chen ST; Lu CH; Yang CY; Chen CC; Lee CC; Hsiao PJ; Jiang JY; Tu ST
    PeerJ; 2020; 8():e9998. PubMed ID: 33240585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center.
    Yoon JH; Hong AR; Choi W; Park JY; Kim HK; Kang HC
    Chonnam Med J; 2021 Sep; 57(3):211-218. PubMed ID: 34621642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in East Asians with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Yang L; Zhang L; He H; Zhang M; An Z
    Diabetes Ther; 2019 Oct; 10(5):1921-1934. PubMed ID: 31376072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of empagliflozin in the management of type 2 diabetes by patient profile.
    Hedrington MS; Davis SN
    Ther Clin Risk Manag; 2015; 11():739-49. PubMed ID: 25999725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus.
    Cho HA; Jung YL; Lee YH; Lee YC; Lee JE; Lee SJ; Jeong SJ; Kim CH
    J Obes Metab Syndr; 2017 Jun; 26(2):107-113. PubMed ID: 31089504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Efficacy of Quadruple Oral Therapy for Type 2 Diabetes in Real-World Practice: A Retrospective Observational Study.
    Cho YK; Lee J; Kim HS; Park JY; Jung CH; Lee WJ
    Diabetes Ther; 2020 Sep; 11(9):2029-2039. PubMed ID: 32696268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Added to Dual or Triple Treatment in Patients with Type 2 Diabetes Mellitus.
    Hong Y; Jeon Y; Choi Y; Chung TK; Lee H
    Diabetes Ther; 2024 Feb; 15(2):487-496. PubMed ID: 38114614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.